UNI-EN 78:Notification for s signed contract for transformation through merger of Unipharm AD in Sopharma AD
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 78 | / | 2017 | |||||||
| Date of issue: | 2017-09-14 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification for s signed contract for transformation through merger of Unipharm AD in Sopharma AD | |||||||||||
| Official market - legal basis | |||||||||||
| art. 17. 1 MAR. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD announces that on 14 September, 2017 in accordance with art. 262e and the following from the Commercial Code Unipharm AD and Sopharma AD signed a contract for transformation through merger of Unipharm AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0. 891512 shares of Sopharma AD. The companies have hired the services of certified appraisers whose reports are a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the responsible Deputy Chairman of the FSC has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Notification_transformation_through_merger_Unipharm.doc Notification_transformation_through_merger_Unipharm.doc | Notification for s signed contract for transformation through merger of Unipharm AD in Sopharma AD | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2017-09-14 | Ognian Donev | Execuitve director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 9.4 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
